The second objective was to compare the determination of NfL in CSF and S, using a highly sensitive ELISA method, with the routine neurodegeneration biomarkers measured in Alzheimer’s disease (AD), and to study their concentrations relative to the degree of cognitive deficit among patients with neurodegenerative diseases. Here, NEFL is linked to early-onset autosomal dominant Alzheimer disease.